OTCMKTS:NRNVF

Nordic Nanovector ASA (NRNVF) Stock Price, News & Analysis

$1.64
0.00 (0.00%)
(As of 10/18/2021)
Today's Range
$1.64
$1.64
50-Day Range
$1.64
$1.64
52-Week Range
$1.64
$1.64
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About Nordic Nanovector ASA

Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutics for hematological cancers in Norway and internationally. The company's lead product candidate is Betalutin, a CD37-targeting antibody-radionuclide-conjugate, which is in Phase 2b clinical trial for the treatment of patients with non-hodgkin lymphoma. Its preclinical development product also includes Alpha37, an anti-CD37 alphaparticle emitting radioimmunoconjugate for treating chronic lymphatic leukemia. Nordic Nanovector ASA has collaboration agreements with Paul Scherrer Institute; Areva Med; LegoChem Bio; and Heidelberg Pharma. The company was formerly known as Nordic Nanovector AS and changed its name to Nordic Nanovector ASA in 2014. Nordic Nanovector ASA was incorporated in 2009 and is headquartered in Oslo, Norway.

NRNVF Stock Price History

NRNVF Stock News Headlines

One trade. One ticker. One week.
Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week?
Nordic Nanovector ASA - allocation of PSUs
One trade. One ticker. One week.
Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week?
Nordic Nanovector ASA: Financial Calendar for 2022
See More Headlines
Receive NRNVF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nordic Nanovector ASA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:NRNVF
CIK
N/A
Fax
N/A
Employees
39
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Ms. Malene Brondberg (Age 48)
    Chief Financial Officer
    Comp: $484.24k
  • Dr. Marco Renoldi (Age 64)
    Chief Operating Officer
    Comp: $537.62k
  • Dr. Lars Nieba Ph.D. (Age 53)
    Chief Technology Officer
    Comp: $575.23k
  • Dr. Jostein Dahle (Age 48)
    Chief Scientific Officer
    Comp: $268.75k
  • Ms. Rosemarie Corrigan (Age 56)
    Chief Quality Officer
    Comp: $407.39k
  • Dr. Christine Wilkinson Blanc M.D.
    M.Sc., Chief Medical Officer
  • Dr. Gabriele Elbl (Age 60)
    VP Global Regulatory Affairs
    Comp: $486.46k
  • Mr. Peter L. Braun
    Chief Exec. Officer
  • Mr. Fredrik Haavind
    Head of Legal & Compliance
  • Ms. Maureen Deehan
    Head of Corp. Devel. & Strategy

NRNVF Stock Analysis - Frequently Asked Questions

How have NRNVF shares performed in 2024?

Nordic Nanovector ASA's stock was trading at $1.6383 at the beginning of 2024. Since then, NRNVF stock has increased by 0.0% and is now trading at $1.6383.
View the best growth stocks for 2024 here
.

How do I buy shares of Nordic Nanovector ASA?

Shares of NRNVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:NRNVF) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners